Brazil · Delayed Price · Currency is BRL Rede D'Or São Luiz Earnings Call Transcripts
Fiscal Year 2026
-
Q2 2026 saw robust revenue, EBITDA, and net income growth, driven by operational efficiency, strong oncology performance, and disciplined capital allocation. SulAmérica improved its loss ratio and beneficiary base, while hospital margins and bed capacity expanded despite contract discontinuations.
-
Revenue and EBITDA grew strongly year-on-year, driven by hospitals and oncology, with margin expansion and improved leverage. SulAmérica added beneficiaries and maintained profitability, while operational efficiency and product innovation supported continued growth.
Fiscal Year 2025
-
Record 2025 results with 27% revenue growth, strong EBITDA, and improved loss ratios. Operational expansion, disciplined capital allocation, and innovation drove performance, while one-off provisioning impacted Q4. Outlook for 2026 remains positive.
-
Revenue grew 10.6% year-on-year to BRL 15.6 billion, with EBITDA up 15.6% and net income rising nearly 20%. Hospital and oncology segments saw strong volume and margin expansion, while SulAmérica improved profitability and loss ratios. Operational efficiency and disciplined capital allocation remain key priorities.
-
Revenue grew 11.5% year-over-year in Q2 2025, with strong EBITDA and net income growth, robust cash generation, and reduced leverage. Operational expansion and digital initiatives are driving efficiency, while SulAmérica continues to grow its beneficiary base and improve profitability.
-
Q1 2025 saw strong revenue, EBITDA, and net income growth, with robust cash generation and improved leverage. SulAmérica added nearly 100,000 new beneficiaries, and operational bed expansion continued. Regulatory and market conditions remain dynamic, but the outlook is positive.
Fiscal Year 2024
-
Solid 2024 results with 10% revenue growth, 33% higher EBITDA, and 81.6% net income increase, driven by hospital expansion and SulAmérica's strong performance. Expecting accelerated bed growth and margin improvement in 2025, with continued focus on operational efficiency and product innovation.
-
Q3 2024 saw 9.1% revenue growth, margin expansion, and strong EBITDA, driven by higher average ticket and complex surgeries. SulAmérica improved claims ratios and beneficiary growth, while robust cash flow enabled continued investment and deleveraging.
-
Q2 2024 saw record patient days, high occupancy, and strong revenue and EBITDA growth, with net income more than doubling YoY. New hospital launches and expansions are set to drive further growth, while SulAmérica improved its loss ratio and beneficiary base.